Kaposi's sarcoma following allogeneic bone marrow transplantation.

abstract：:Following engraftment of donor hematopoietic cells and induction of host-versus-graft tolerance, immunocompetent lymphocytes of donor origin can induce graft-versus-leukemia (GVL) and graft-versus-tumor (GVT) effects. Engraftment of allogeneic bone marrow cells can be accomplished following non-myeloablative condition...

journal_title：Bone marrow transplantation

authors： Slavin S,Or R,Prighozina T,Gurevitch O,Aker M,Panighari S,Shapira M,Nagler A

更新日期：2000-05-01 00:00:00

abstract：:Patients with leukemia relapsing after allogeneic hematopoietic SCT have a dismal prognosis. A second SCT offers a further opportunity for cure, but has a high rate of treatment failure. To determine the utility of this option, we analyzed 59 consecutive patients relapsing after a myeloablative HLA-matched sibling T c...

journal_title：Bone marrow transplantation

authors： McIver ZA,Yin F,Hughes T,Battiwalla M,Ito S,Koklanaris E,Haggerty J,Hensel NF,Barrett AJ

更新日期：2013-09-01 00:00:00

abstract：:Two hundred and ten bronchoalveolar lavage (BAL) samples were obtained from 50 patients 10 days before and on defined days after allogeneic bone marrow transplantation (BMT). The samples were examined for human cytomegalovirus (HCMV) and human herpesvirus-6 (HHV-6) by polymerase chain reaction (PCR). Fifteen patients ...

journal_title：Bone marrow transplantation

authors： Buchbinder S,Elmaagacli AH,Schaefer UW,Roggendorf M

更新日期：2000-09-01 00:00:00

abstract：:Results of allogeneic bone marrow transplantation (BMT) are still impaired due mainly to acute graft-versus-host disease (GVHD). Successful T cell depletion may abolish GVHD but causes increased rates of rejection and relapse. In vivo blocking of the CD25 receptor on T cells induces efficient and selective immunosuppr...

journal_title：Bone marrow transplantation

authors： Blaise D,Olive D,Hirn M,Viens P,Lafage M,Attal M,Stoppa AM,Gabert J,Gastaut JA,Camerlo J

更新日期：1991-08-01 00:00:00

abstract：:In order to identify cytomegalovirus (CMV)-seropositive patients who are at risk of developing CMV infection following first allogeneic hematopoietic cell transplantation (allo-HCT), we built up a scoring system based on patient/donor characteristics and transplantation modalities. To this end, 3690 consecutive patien...

journal_title：Bone marrow transplantation

authors： Beauvais D,Drumez E,Blaise D,Peffault de Latour R,Forcade E,Ceballos P,Uyttebroeck A,Labussière H,Nguyen S,Bourhis JH,Chevallier P,Thiebaut A,Poiré X,Maury S,Deconinck E,Cluzeau T,Brissot E,Huynh A,Rubio MT,Duhamel

更新日期：2020-12-18 00:00:00

abstract：:The incidence of secondary malignancy following autologous stem cell transplantation (ASCT) is increasing. We describe a patient with stage IVB Hodgkin's disease who developed primary amelanotic malignant melanoma of the tongue 18 months following autologous stem cell transplantation. She was treated by partial glosse...

journal_title：Bone marrow transplantation

authors： Ben-Yosef R,Braverman I,Saah D,Nagler R,Shohat S,Or R,Nagler A

更新日期：1996-11-01 00:00:00

abstract：:We retrospectively reviewed the pulmonary toxicity of six high dose chemotherapy protocols using four chemotherapy regimens in the treatment of solid tumors. All protocols used either high dose cyclophosphamide or ifosfamide in combination with one to three additional chemotherapeutic agents. In each protocol autologo...

journal_title：Bone marrow transplantation

authors： Seiden MV,Elias A,Ayash L,Hunt M,Eder JP,Schnipper LE,Frei E 3rd,Antman KH

更新日期：1992-07-01 00:00:00

abstract：:Numerous studies have reported the feasibility and safety of autologous SCT (ASCT) in patients with multiple myeloma (MM) and mild to moderate renal impairment, but there are limited data in dialysis-dependent patients. In this retrospective study, we reviewed the toxicities and efficacy outcomes of 33  MM patients wi...

journal_title：Bone marrow transplantation

authors： St Bernard R,Chodirker L,Masih-Khan E,Jiang H,Franke N,Kukreti V,Tiedemann R,Trudel S,Reece D,Chen CI

更新日期：2015-01-01 00:00:00

abstract：:Hepatic venocclusive disease (VOD) is a common toxicity associated with myeloablative chemotherapy or chemoradiotherapy used to prepare patients for stem cell transplantation. A sizable proportion of patients who develop VOD die. It is clear that injury to endothelial cells and hepatocytes in zone 3 of the liver acinu...

journal_title：Bone marrow transplantation

authors： Bearman SI

更新日期：2001-06-01 00:00:00

abstract：:The role of high-dose therapy and autologous stem cell transplantation (ASCT) in the treatment of patients with Ewing's sarcoma (EWS) remains uncertain. From November 1985 to September 1994, 13 patients aged 16-30 years (median 20.5) received high-dose melphalan (HDM) 140-200 mg/m2 +/- 500 cGy TBI followed by ASCT for...

journal_title：Bone marrow transplantation

authors： Stewart DA,Gyonyor E,Paterson AH,Arthur K,Temple W,Schachar NS,Klassen J,Brown C,Russell JA

更新日期：1996-08-01 00:00:00

abstract：:The effect of prophylactic intravenous administration of a cytomegalovirus (CMV) hyperimmune globulin with a high titer of neutralizing antibodies plus oral acyclovir was studied in 93 consecutive bone marrow transplant recipients. In spite of receiving blood products unscreened for CMV only six patients developed CMV...

journal_title：Bone marrow transplantation

authors： Einsele H,Vallbracht A,Friese M,Schmidt H,Haen M,Dopfer R,Niethammer D,Waller HD,Ehninger G

更新日期：1988-11-01 00:00:00

abstract：:Hematopoietic progenitor cell levels were monitored in the peripheral blood of ten healthy adults receiving a single dose of recombinant human granulocyte colony-stimulating factor (rhG-CSF). The objective was to determine the time and number of progenitor cells released into the peripheral blood, induced by a single ...

journal_title：Bone marrow transplantation

authors： Schwinger W,Mache C,Urban C,Beaufort F,Töglhofer W

更新日期：1993-06-01 00:00:00

abstract：:Microangiopathic hemolytic anemia (MAHA) is a well-described complication of stem cell transplantation. Plasmapheresis is one modality utilized as therapy for patients who develop this complication. However, plasmapheresis may alter whole blood levels of certain medications and its effect on tacrolimus in bone marrow ...

journal_title：Bone marrow transplantation

authors： Hale GA,Reece DE,Munn RK,Kniska AB,Phillips GL

更新日期：2000-02-01 00:00:00

abstract：:We report the results of a retrospective analysis in 27 pediatric patients who received low-dose MTX as the second-line treatment for steroid-refractory or -dependent acute and chronic GVHD. Between July 2000 and May 2006, 10 patients with aGVHD and 17 with cGVHD were treated with MTX at a dose of 3-10 mg/m(2) weekly....

journal_title：Bone marrow transplantation

authors： Inagaki J,Nagatoshi Y,Hatano M,Isomura N,Sakiyama M,Okamura J

更新日期：2008-03-01 00:00:00

abstract：:The management of acute leukaemia which relapses following an allogeneic stem cell transplant remains a major challenge. In this review we summarize the outcomes of the currently available treatment modalities and discuss emerging novel approaches. ...

journal_title：Bone marrow transplantation

authors： Shaw BE,Russell NH

更新日期：2008-03-01 00:00:00

abstract：:Allogeneic BMT is potentially curative for patients with acute myelogenous leukemia (AML) in first remission. However, many patients relapse after transplantation. Various immunotherapeutic options have been attempted with variable success in preventing relapse. Early identification of patients at high risk for relaps...

journal_title：Bone marrow transplantation

authors： Kumar S,Chen MG,Gastineau DA,Gertz MA,Inwards DJ,Lacy MQ,Tefferi A,Litzow MR

更新日期：2001-11-01 00:00:00

abstract：:Forty-five adult HLA-matched sibling BMT recipients were randomized to receive inactivated poliovirus vaccine (IPV) at 6, 8 and 14 months (early group, n = 23) or at 18, 20 and 26 months after BMT (late group, n = 22). Ninety-five percent of the early group patients had protective antibody titres of > or = 4 to poliov...

journal_title：Bone marrow transplantation

authors： Parkkali T,Stenvik M,Ruutu T,Hovi T,Volin L,Ruutu P

更新日期：1997-10-01 00:00:00

abstract：:HA-1(H) is one of the most attractive minor histocompatibility antigens (mHA) as a target for immunotherapy of hematopoietic malignancies, but HLA-A*0201 and HLA-B60 molecules capable of presenting HA-1(H)-derived peptides are less common in eastern Asian populations when compared with Caucasian populations. Therefore...

journal_title：Bone marrow transplantation

authors： Torikai H,Akatsuka Y,Miyauchi H,Terakura S,Onizuka M,Tsujimura K,Miyamura K,Morishima Y,Kodera Y,Kuzushima K,Takahashi T

更新日期：2007-07-01 00:00:00

abstract：:Thirty thalassaemia patients received iron reduction starting at around 3 months post transplant. Sixteen received desferrioxamine and nine had phlebotomy, five patients had desferrioxamine followed by phlebotomy. The desferrioxamine group had higher serum ferritin levels at the start of iron reduction as compared to ...

journal_title：Bone marrow transplantation

authors： Li CK,Lai DH,Shing MM,Chik KW,Lee V,Yuen PM

更新日期：2000-03-01 00:00:00

abstract：:Serological, cellular and DNA-RFLP (restriction fragment length polymorphism) methods of determining HLA compatibility between 10 leukaemic patients and potential related bone marrow donors were systematically compared. DR beta/DQ alpha/DQ beta/DNA-RFLP typing of these families gave results in agreement with those obt...

journal_title：Bone marrow transplantation

authors： Howell WM,Evans PR,Spellerberg MB,Wilson PJ,Smith JL

更新日期：1989-01-01 00:00:00

abstract：:High-dose immunoablative chemotherapy with autologous haematopoietic cell support might be beneficial in the treatment of intractable forms of MS. We mobilised PBPC in 11 patients with secondary progressive MS and finally eight patients were grafted after high-dose BEAM chemotherapy with either in vitro or in vivo T c...

journal_title：Bone marrow transplantation

authors： Kozák T,Havrdová E,Pit'ha J,Gregora E,Pytlík R,Maaloufová J,Marecková H,Kobylka P,Vodvárková S

更新日期：2000-03-01 00:00:00

abstract：:Adenovirus has been recognised as an important pathogen in BMT recipients, especially in patients with GVHD and those receiving T cell-depleted allografts. We report adenovirus infections from an ongoing surveillance study in four patients after a non-myeloablative transplant and their improved outcome following withd...

journal_title：Bone marrow transplantation

authors： Chakrabarti S,Collingham KE,Fegan CD,Pillay D,Milligan DW

更新日期：2000-08-01 00:00:00

abstract：:Data on long-term follow-up of donors for hematopoietic stem cell transplantation (HSCT) are limited. Donors of 612 adult allogeneic HSCT were studied, at a median of 81 (14-181) months post-HSC donation. Nine donors had severe health problems. Five donors died from aggressive malignancies or terminal illness, at a me...

journal_title：Bone marrow transplantation

authors： Au WY,Lie AK,Cheng JW,Liang R,Kwong YL

更新日期：2006-03-01 00:00:00

abstract：:Progressive multifocal leukoencephalopathy (PML) is a rare subacute demyelinating disorder of the central nervous system (CNS) caused by the DNA JC human polyomavirus. In immunocompromised hosts, PML is caused by reactivation of a latent infection rather than de novo primary exposure. PML in the setting of hematopoiet...

journal_title：Bone marrow transplantation

authors： Kharfan-Dabaja MA,Ayala E,Greene J,Rojiani A,Murtagh FR,Anasetti C

更新日期：2007-01-01 00:00:00

abstract：:Seventeen patients with Philadelphia (Ph) chromosome-positive chronic myeloid leukemia (CML) were treated with the ICE regimen plus G-CSF with the aim of mobilizing and collecting Ph-negative peripheral stem cells (PSC) in the setting of an autotransplant program. Fifteen patients had CML in first chronic phase (CP), ...

journal_title：Bone marrow transplantation

authors： Boqué C,Petit J,Sarrá J,Cancelas JA,Muñoz J,Español JI,de la Banda E,Aventin A,Berlanga J,Ferrá C,Amill B,Torrico C,Azqueta C,Llucià M,García J,Grañena A

更新日期：1996-11-01 00:00:00

abstract：:Twenty three allogeneic bone marrow transplant (BMT) patients with female donors and 23 female autologous transplant patients were assessed for clonality status after transplant to determine the nature of haemopoietic reconstitution. The X chromosome probes PGK, HPRT and M27 beta were used to assess clonality by analy...

journal_title：Bone marrow transplantation

authors： Saunders MJ,Jowitt SN,Yin JA

更新日期：1995-01-01 00:00:00

abstract：:Microsporidia are obligate, intracellular protozoal parasites that can be pathogenic in immunocompromised individuals. The majority of cases of microsporidiosis have been documented in patients with HIV, and only a few case reports exist of infection in solid organ transplant patients. We report the first case of pulm...

journal_title：Bone marrow transplantation

authors： Teachey DT,Russo P,Orenstein JM,Didier ES,Bowers C,Bunin N

更新日期：2004-02-01 00:00:00

abstract：:Ataxia telangiectasia is a genetic instability syndrome characterized by neurodegeneration, immunodeficiency, severe bronchial complications, hypersensitivity to radiotherapy and an elevated risk of malignancies. Repopulation with ATM-competent bone marrow-derived cells (BMDCs) significantly prolonged the lifespan and...

journal_title：Bone marrow transplantation

authors： Pietzner J,Merscher BM,Baer PC,Duecker RP,Eickmeier O,Fußbroich D,Bader P,Del Turco D,Henschler R,Zielen S,Schubert R

更新日期：2016-04-01 00:00:00

abstract：:Increased use of novel agents and autologous stem cell transplantation has led to a significant improvement in PFS and overall survival in patients with multiple myeloma. Despite improved treatment strategies, most patients eventually relapse due to persistent low levels of disease in the bone marrow. Increasingly sen...

journal_title：Bone marrow transplantation

authors： Sherrod AM,Hari P,Mosse CA,Walker RC,Cornell RF

更新日期：2016-01-01 00:00:00

abstract：:We report a patient with pre-existing end-stage renal disease (ESRD) who underwent successful matched related donor allogeneic bone marrow transplantation for AML in second complete remission (CR2) using conditioning with high-dose cyclophosphamide (CY, 60 mg/kg/day x 2) and TBI (165 cGy twice daily x 4 days). The tim...

journal_title：Bone marrow transplantation

authors： Perry JJ,Fleming RA,Rocco MV,Petros WP,Bleyer AJ,Radford JE Jr,Powell BL,Hurd DD

更新日期：1999-04-01 00:00:00